The Therapeutics Development and Supply-Active Pharmaceutical Ingredient (TDS-API) develops creative large molecule solutions to address significant unmet medical needs in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. The TDS-API Process Development organization is seeking innovative candidates with interest in Gene Therapy process development.
The Adeno-associated virus (AAV) vectors are primary gene therapy platform for a variety of human diseases. The development of a robust and scalable chromatography purification process to separate empty and full AAV particles at large scale remains a challenge. The Co-Op will be responsible for leading a collaborative project to evaluate the use of MgCl2 (and alternatives) in the purification of AAV. Initial proof of concept studies shows that MgCl2 wash helps in removing empty capsids and allows a step gradient elution to achieve a high purity. The overall goal of this project is to better understand the effect that the MgCl2 (and alternatives) on the full/empty capsid binding and purification.
Johnson & Johnson Family of Companies are equal opportunity employers, and all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, genetic information, national origin, protected veteran status, disability status, or any other characteristic protected by law.